United Therapeutics CorpUTHR
Price$541.89Intrinsic value$398.2527% below price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $398.25median of 6 methods · middle span $324-$782based on filings through 30 Jun 2026
Market Price $541.89Price as of 30 Sep 2026
Margin of Safety -26.5%as of 30 Sep 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 3.3% (near-term consensus, capped) · years 2–5: 8.7%/yr (balance of the path).7.6% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 68.4%Yr 78.2%Yr 88.0%Yr 97.8%Yr 107.6%
8.7% → 7.6%
Years 11–20: glide to long-run rate
Per-year rates
Yr 117.1%Yr 126.6%Yr 136.2%Yr 145.7%Yr 155.3%Yr 164.8%Yr 174.4%Yr 183.9%Yr 193.5%Yr 203.0%
7.6% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 2 windows (5/7y) (limited history)15.2%
Discount rate (cost of equity) 8.1%
Volatility vs market (adjusted beta)0.71

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetUnited Therapeutics CorpUTHRHealth Care
Valuation
P/E19.4×
P/S6.8×
P/B3.6×
EV / Revenue6.2×
EV / EBITDA11.8×
Profitability
Gross margin82.9%
Operating margin41.7%
Net margin41.6%
FCF margin34.6%
Returns
ROE20.5%
ROA18.2%
ROIC28.5%
Growth
Revenue growth (YoY)9.6%
5-yr fwd EPS growth7.6%
Financial strength
Debt / Equity0.00×
Current ratio5.73×
Altman Z-Score19.0
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.